CNP
52
-2
BK
65
2
FOX
70
-3
GT
49
2
ICE
57
2
F
42
2
SRE
45
-2
AES
49
-2
STI
12
-7
NRG
37
-2
LNC
32
3
GOOGL
64
-2
DLTR
59
4
STZ
40
-2
CLX
65
2
WHR
59
-2
MNST
59
7
EQR
39
2
K
56
3
KIM
58
-2
CNP
52
-2
BK
65
2
FOX
70
-3
GT
49
2
ICE
57
2
F
42
2
SRE
45
-2
AES
49
-2
STI
12
-7
NRG
37
-2
LNC
32
3
GOOGL
64
-2
DLTR
59
4
STZ
40
-2
CLX
65
2
WHR
59
-2
MNST
59
7
EQR
39
2
K
56
3
KIM
58
-2
Financhill
Back

Keros Therapeutics 10K Form

Sell
12

KROS
Keros Therapeutics

Last Price:
$16.42
Seasonality Move:
5.39%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KROS News And Ratings

See the #1 stock for the next 7 days that we like better than KROS

KROS Financial Statistics

Sales & Book Value

Annual Sales: $151K
Cash Flow: $-30.9M
Price / Cash Flow: 0
Annual Sales: $13.57
Price / Book: 1.28

Profitability

EPS (TTM): -5.21000
Net Income (TTM): $-181.6M
Gross Margin: --
Return on Equity: -44.6%
Return on Assets: -40.96%

Keros Therapeutics Earnings Forecast

Key Keros Therapeutics Financial Ratios

  • The Research & Development expenses have been 89,574.83% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of KROS is -101,319.21% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Keros Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KROS
CUSIP: 492327
Website: kerostx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 19.03
Quick Ratio: 18.36

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KROS Technical Analysis vs Fundamental Analysis

Sell
12
Keros Therapeutics (KROS) is a Sell

Is Keros Therapeutics a Buy or a Sell?